Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy
Condition(s) studied
Investigational drug(s) / intervention(s)
Sucrose Iron,subcutaneous recombinant human erythropoietin,intravenous vitamin C: Patients in the experimental group will receive a combination therapy consisting of intravenous sucrose iron (200 mg), subcutaneous recombinant human erythropoietin (150 IU/kg), and intravenous vitamin C (2 g), administered once daily for three consecutive days within the week prior to surgery.
Routine perioperative management: Routine perioperative management based on clinical judgment, including observation, monitoring, and standard nursing practices.
Study summary
This is a sub-study of the Preoperative Combined Iron Therapy trail in which some participants will be additionally randomized to combined iron supplementation or standarded treatment control to evaluate the impact on long-term outcomes.
Eligibility
Primary outcome measure(s)
- Quality of Life (EQ-5D) — 1 year postoperatively (±30 days)
Assessment of health-related quality of life using the EuroQol 5-Dimension (EQ-5D) questionnaire
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Anesthesiology, Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | Zhejiang | Recruiting |
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06968936 on ClinicalTrials.gov ↗ ← All trials in China